Created at	Source	Raw Value	Validated value
Sept. 18, 2022, 3 a.m.	usa	Antibody durability;Geometric mean titer fold change;Safety assessment 1;Safety assessment 2;SARS-CoV-2 infection;Seroconversion;Seroconversion in participants with and without evidence of past infection;Seroprotection;Seroprotection in participants with and without evidence of past infection;Spike antibody GMT in participants with and without evidence of past infection	Antibody durability;Geometric mean titer fold change;Safety assessment 1;Safety assessment 2;SARS-CoV-2 infection;Seroconversion;Seroconversion in participants with and without evidence of past infection;Seroprotection;Seroprotection in participants with and without evidence of past infection;Spike antibody GMT in participants with and without evidence of past infection